{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:19:22Z","timestamp":1791544762201,"version":"4.3.4"},"reference-count":341,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Background<\/jats:title>\n Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies. For both PICO and narrative questions, the Evidence to Decision framework was used to formulate the recommendations.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The task force committee concluded with recommendations for 25 PICO and 28 narrative questions, regarding ILD in the context of systemic sclerosis, rheumatoid arthritis (RA), idiopathic inflammatory myopathies, Sj\u00f6gren disease (SjD), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). In four narrative questions, regarding screening and assessment of risk for ILD progression in MCTD, SjD and SLE and one PICO question regarding pirfenidone in CTD-ILD other than RA-ILD, the task force had insufficient evidence to support recommendations. Screening, diagnostic, monitoring and treatment algorithms were developed based on the recommendations and usual clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n We provide practical guidance by evidence-based recommendations to clinicians for each of the CTDs. In many cases there is low certainty or absence of evidence and we encourage further research to fill these gaps.<\/jats:p>\n <\/jats:sec>","DOI":"10.1183\/13993003.02533-2024","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T09:35:12Z","timestamp":1756978512000},"page":"2402533","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease"],"prefix":"10.1183","volume":"67","author":[{"given":"Katerina M.","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Gheorghiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5295-2877","authenticated-orcid":false,"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Vikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-1519","authenticated-orcid":false,"given":"Nikoleta","family":"Bizymi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-7582","authenticated-orcid":false,"given":"Ilaria","family":"Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-0002","authenticated-orcid":false,"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera J.","family":"Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-0307","authenticated-orcid":false,"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-1386","authenticated-orcid":false,"given":"Aurelie","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-2284","authenticated-orcid":false,"given":"Venerino","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-8097","authenticated-orcid":false,"given":"Britta","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta A.","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7671-1023","authenticated-orcid":false,"given":"Mary E.","family":"Strek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sverzellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-6941","authenticated-orcid":false,"given":"Paul","family":"Studenic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7466-7973","authenticated-orcid":false,"given":"Jibril","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blin","family":"Nagavci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomy","family":"Tonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-3455","authenticated-orcid":false,"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2026012205050798000_67.1.2402533.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0194"},{"key":"2026012205050798000_67.1.2402533.2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.reuma.2021.07.008","article-title":"Screening of interstitial lung disease in patients with rheumatoid arthritis: a systematic review","volume":"18","author":"Garrote-Corral","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2026012205050798000_67.1.2402533.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0741"},{"key":"2026012205050798000_67.1.2402533.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2018"},{"key":"2026012205050798000_67.1.2402533.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"2026012205050798000_67.1.2402533.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2026012205050798000_67.1.2402533.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2026012205050798000_67.1.2402533.8","doi-asserted-by":"crossref","unstructured":"Higgins J , Thomas J , Chandler J , et al. Cochrane Handbook for Systematic Reviews of Interventions: Version 6.0. London, Cochrane, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2026012205050798000_67.1.2402533.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.03.013"},{"key":"2026012205050798000_67.1.2402533.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2016"},{"key":"2026012205050798000_67.1.2402533.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2089"},{"key":"2026012205050798000_67.1.2402533.12","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.41415","article-title":"Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis","volume":"72","author":"Bernstein","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.13","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0486OC"},{"key":"2026012205050798000_67.1.2402533.15","doi-asserted-by":"publisher","DOI":"10.1159\/000335473"},{"key":"2026012205050798000_67.1.2402533.16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00296-017-3916-x","article-title":"Interstitial lung disease in systemic sclerosis: data from the Spanish Scleroderma Study Group","volume":"38","author":"Sanchez-Cano","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026012205050798000_67.1.2402533.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171362"},{"key":"2026012205050798000_67.1.2402533.18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/03009742.2015.1011228","article-title":"Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography","volume":"44","author":"Sperandeo","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2026012205050798000_67.1.2402533.19","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.10.635"},{"key":"2026012205050798000_67.1.2402533.21","doi-asserted-by":"publisher","DOI":"10.1136\/thx.56.8.622"},{"key":"2026012205050798000_67.1.2402533.22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9609016"},{"key":"2026012205050798000_67.1.2402533.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1492-5"},{"key":"2026012205050798000_67.1.2402533.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2009.01376.x"},{"key":"2026012205050798000_67.1.2402533.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes167"},{"key":"2026012205050798000_67.1.2402533.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006122"},{"key":"2026012205050798000_67.1.2402533.27","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600844381"},{"key":"2026012205050798000_67.1.2402533.28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-022-02786-x","article-title":"Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases","volume":"24","author":"Hoffmann","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026012205050798000_67.1.2402533.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201072"},{"key":"2026012205050798000_67.1.2402533.30","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.3390\/jcm10184114","article-title":"Lung ultrasound in the screening of pulmonary interstitial involvement secondary to systemic connective tissue disease: a prospective pilot study involving 180 patients","volume":"10","author":"Buda","year":"2021","journal-title":"J Clin Med"},{"key":"2026012205050798000_67.1.2402533.31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5606\/ArchRheumatol.2016.5849","article-title":"Effectiveness of thoracic ultrasonography in the evaluation of the severity of pulmonary involvement in patients with systemic sclerosis","volume":"31","author":"\u00c7akir Edis","year":"2016","journal-title":"Arch Rheumatol"},{"key":"2026012205050798000_67.1.2402533.32","first-page":"156","article-title":"Transthoracic ultrasound in the detection of interstitial pulmonary fibrosis in patients with rheumatic connective tissue diseases","volume":"76","author":"Fehr","year":"2018","journal-title":"Bull Hosp Jt Dis (2013)"},{"key":"2026012205050798000_67.1.2402533.33","doi-asserted-by":"crossref","first-page":"Si56","DOI":"10.1093\/rheumatology\/keab801","article-title":"Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening","volume":"61","author":"Gargani","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.34","doi-asserted-by":"crossref","first-page":"105407","DOI":"10.1016\/j.jbspin.2022.105407","article-title":"The emerging role of ultrasound in detecting interstitial lung disease in patients with rheumatoid arthritis","volume":"89","author":"Gutierrez","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2026012205050798000_67.1.2402533.35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/RHU.0000000000000860","article-title":"Lung ultrasound as a screening method for interstitial lung disease in patients with systemic sclerosis","volume":"25","author":"Hassan","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.36","first-page":"199","article-title":"Ultrasound screening for interstitial lung disease in rheumatoid arthritis","volume":"32","author":"Moazedi-Fuerst","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.11152\/mu.2014.2066.161.am1so2","article-title":"Comparison of a new, modified lung ultrasonography technique with high-resolution CT in the diagnosis of the alveolo-interstitial syndrome of systemic scleroderma","volume":"16","author":"Mohammadi","year":"2014","journal-title":"Med Ultrason"},{"key":"2026012205050798000_67.1.2402533.38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.reuma.2019.05.004","article-title":"Subclinical interstitial lung disease in patients with systemic sclerosis. A pilot study on the role of ultrasound","volume":"17","author":"Reyes-Long","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2026012205050798000_67.1.2402533.39","doi-asserted-by":"crossref","first-page":"e0566","DOI":"10.1097\/MD.0000000000010566","article-title":"Ultrasound B-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: cut-off point definition for the presence of significant pulmonary fibrosis","volume":"97","author":"Tardella","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026012205050798000_67.1.2402533.40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00296-017-3893-0","article-title":"Interstitial lung disease in South Africans with systemic sclerosis","volume":"38","author":"Ashmore","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026012205050798000_67.1.2402533.41","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-3987-3"},{"key":"2026012205050798000_67.1.2402533.42","doi-asserted-by":"crossref","first-page":"9468","DOI":"10.1038\/s41598-019-45990-7","article-title":"Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis","volume":"9","author":"Bocchino","year":"2019","journal-title":"Sci Rep"},{"key":"2026012205050798000_67.1.2402533.43","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/RHU.0000000000000815","article-title":"Nailfold videocapillaroscopy changes are associated with the presence and severity of systemic sclerosis-related interstitial lung disease","volume":"25","author":"Caetano","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.44","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13452"},{"key":"2026012205050798000_67.1.2402533.45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13075-018-1775-9","article-title":"Quantitative videocapillaroscopy correlates with functional respiratory parameters: a clue for vasculopathy as a pathogenic mechanism for lung injury in systemic sclerosis","volume":"20","author":"Guillen-Del-Castillo","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2026012205050798000_67.1.2402533.46","first-page":"657","article-title":"Study of the correlation between HRCT semi-quantitative scoring, concentration of alveolar nitric oxide, and clinical-functional parameters of systemic sclerosis-induced interstitial lung disease","volume":"93","author":"Hoang-Duc","year":"2020","journal-title":"Yale J Biol Med"},{"key":"2026012205050798000_67.1.2402533.47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/acr.20336","article-title":"Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry","volume":"63","author":"Khimdas","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.48","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"2026012205050798000_67.1.2402533.49","first-page":"1081","article-title":"Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies","volume":"56","author":"Markusse","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-019-1919-6","article-title":"Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study","volume":"21","author":"Matsuda","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026012205050798000_67.1.2402533.51","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2057-x"},{"key":"2026012205050798000_67.1.2402533.52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008980"},{"key":"2026012205050798000_67.1.2402533.53","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/resp.13988","article-title":"Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression","volume":"26","author":"Stock","year":"2021","journal-title":"Respirology"},{"key":"2026012205050798000_67.1.2402533.55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10067-021-05918-x","article-title":"Association of quantitative computed tomography indices with lung function and extent of pulmonary fibrosis in patients with systemic sclerosis","volume":"41","author":"Temiz Karadag","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2397198319869564","article-title":"Prediction of organ involvement and survival in systemic sclerosis patients in the first 5\u2005years from diagnosis","volume":"5","author":"van den Hombergh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2026012205050798000_67.1.2402533.57","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1007\/s10067-020-05105-4","article-title":"Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment","volume":"39","author":"Vanaken","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.58","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.semarthrit.2021.07.018","article-title":"Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in Flanders: a retrospective cohort study","volume":"51","author":"Vandecasteele","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026012205050798000_67.1.2402533.59","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"2026012205050798000_67.1.2402533.60","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.61","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.62","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"35","author":"Iniesta Arandia","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.63","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.59"},{"key":"2026012205050798000_67.1.2402533.64","doi-asserted-by":"crossref","first-page":"406927","DOI":"10.1155\/2013\/406927","article-title":"Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease","volume":"2013","author":"Chen","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2026012205050798000_67.1.2402533.65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/cells9030691","article-title":"Anti-HLA class II antibodies correlate with C-reactive protein levels in patients with rheumatoid arthritis associated with interstitial lung disease","volume":"9","author":"Del Angel-Pablo","year":"2020","journal-title":"Cells"},{"key":"2026012205050798000_67.1.2402533.66","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1394"},{"key":"2026012205050798000_67.1.2402533.67","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05585-y"},{"key":"2026012205050798000_67.1.2402533.68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203160"},{"key":"2026012205050798000_67.1.2402533.69","doi-asserted-by":"publisher","DOI":"10.3109\/03009748609098205"},{"key":"2026012205050798000_67.1.2402533.70","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.71","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq035"},{"key":"2026012205050798000_67.1.2402533.72","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04846-1"},{"key":"2026012205050798000_67.1.2402533.73","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10067-021-05655-1","article-title":"Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis","volume":"40","author":"Mena-Vazquez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.reuma.2019.06.001","article-title":"Analysis of clinical\u2013analytical characteristics in patients with rheumatoid arthritis and interstitial lung disease: case\u2013control study","volume":"17","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2026012205050798000_67.1.2402533.75","doi-asserted-by":"crossref","first-page":"e17088","DOI":"10.1097\/MD.0000000000017088","article-title":"High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities","volume":"98","author":"Salaffi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026012205050798000_67.1.2402533.76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5606\/ArchRheumatol.2018.6691","article-title":"Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy?","volume":"33","author":"Sargin","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2026012205050798000_67.1.2402533.77","doi-asserted-by":"crossref","first-page":"105948","DOI":"10.1016\/j.rmed.2020.105948","article-title":"Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study","volume":"166","author":"Wu","year":"2020","journal-title":"Respir Med"},{"key":"2026012205050798000_67.1.2402533.78","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.50012"},{"key":"2026012205050798000_67.1.2402533.79","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.80","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.semarthrit.2021.04.012","article-title":"The phenotype of myositis patients with anti-Ku autoantibodies","volume":"51","author":"Casal-Dominguez","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026012205050798000_67.1.2402533.81","doi-asserted-by":"crossref","first-page":"648570","DOI":"10.1155\/2013\/648570","article-title":"A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy","volume":"2013","author":"Cen","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2026012205050798000_67.1.2402533.82","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3349\/ymj.2021.62.5.424","article-title":"Comparison of the 2017 EULAR\/ACR criteria with clinicoserologic criteria for the classification of idiopathic inflammatory myopathies in Korean patients","volume":"62","author":"Chung","year":"2021","journal-title":"Yonsei Med J"},{"key":"2026012205050798000_67.1.2402533.83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","article-title":"Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies","volume":"22","author":"Ge","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012205050798000_67.1.2402533.84","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3346\/jkms.2016.31.3.389","article-title":"Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a Korean retrospective cohort study","volume":"31","author":"Go","year":"2016","journal-title":"J Korean Med Sci"},{"key":"2026012205050798000_67.1.2402533.85","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s10067-019-04501-9","article-title":"Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis","volume":"38","author":"Hu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.86","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s10072-020-04911-7","article-title":"The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease","volume":"42","author":"Huang","year":"2021","journal-title":"Neurol Sci"},{"key":"2026012205050798000_67.1.2402533.87","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker518"},{"key":"2026012205050798000_67.1.2402533.88","first-page":"1012","article-title":"Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"key":"2026012205050798000_67.1.2402533.89","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.90","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00296-012-2545-7","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients","volume":"33","author":"Sun","year":"2013","journal-title":"Rheumatol Int"},{"key":"2026012205050798000_67.1.2402533.91","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12016-020-08814-5","article-title":"Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis","volume":"60","author":"Vojinovic","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026012205050798000_67.1.2402533.92","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s10067-022-06089-z","article-title":"Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.93","doi-asserted-by":"crossref","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"key":"2026012205050798000_67.1.2402533.94","doi-asserted-by":"crossref","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"2026012205050798000_67.1.2402533.95","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.96","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jocn.2020.01.060","article-title":"Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy","volume":"74","author":"Huang","year":"2020","journal-title":"J Clin Neurosci"},{"key":"2026012205050798000_67.1.2402533.97","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.98","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh575"},{"key":"2026012205050798000_67.1.2402533.99","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev300"},{"key":"2026012205050798000_67.1.2402533.100","doi-asserted-by":"crossref","first-page":"105895","DOI":"10.1016\/j.rmed.2020.105895","article-title":"Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjogren syndrome","volume":"163","author":"Buvry","year":"2020","journal-title":"Respir Med"},{"key":"2026012205050798000_67.1.2402533.101","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","article-title":"A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjogren's syndrome-related interstitial lung disease in a Chinese population","volume":"37","author":"Dong","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.102","doi-asserted-by":"crossref","first-page":"e11003","DOI":"10.1097\/MD.0000000000011003","article-title":"Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjogren syndrome patients: a case-control study","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026012205050798000_67.1.2402533.103","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1080\/07853890.2021.1965205","article-title":"Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population: a retrospective analysis of 735 patients","volume":"53","author":"Guo","year":"2021","journal-title":"Ann Med"},{"key":"2026012205050798000_67.1.2402533.104","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.13881"},{"key":"2026012205050798000_67.1.2402533.105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12890-022-01868-5","article-title":"Interstitial lung disease in primary Sjogren's syndrome","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012205050798000_67.1.2402533.106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sjogren's syndrome","volume":"16","author":"Roca","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2026012205050798000_67.1.2402533.107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fmed.2020.00332","article-title":"Lung involvement in primary Sjogren's syndrome-an under-diagnosed entity","volume":"7","author":"Sogkas","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1590\/abd1806-4841.20175476","article-title":"Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus","volume":"92","author":"Su","year":"2017","journal-title":"An Bras Dermatol"},{"key":"2026012205050798000_67.1.2402533.109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.resinv.2019.04.005","article-title":"Clinical features of interstitial pneumonia associated with systemic lupus erythematosus","volume":"57","author":"Toyoda","year":"2019","journal-title":"Respir Investig"},{"key":"2026012205050798000_67.1.2402533.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.02.015"},{"key":"2026012205050798000_67.1.2402533.111","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"2026012205050798000_67.1.2402533.112","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.113","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"2026012205050798000_67.1.2402533.114","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chest.2022.09.044","article-title":"Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European scleroderma trials and research","volume":"163","author":"Hoffmann-Vold","year":"2023","journal-title":"Chest"},{"key":"2026012205050798000_67.1.2402533.115","doi-asserted-by":"crossref","first-page":"e0181692","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PLoS One"},{"key":"2026012205050798000_67.1.2402533.116","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes289"},{"key":"2026012205050798000_67.1.2402533.117","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.15-0003","article-title":"Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis","volume":"148","author":"Ryerson","year":"2015","journal-title":"Chest"},{"key":"2026012205050798000_67.1.2402533.118","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213708"},{"key":"2026012205050798000_67.1.2402533.119","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/resp.13309","article-title":"Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease","volume":"23","author":"Winstone","year":"2018","journal-title":"Respirology"},{"key":"2026012205050798000_67.1.2402533.120","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213201"},{"key":"2026012205050798000_67.1.2402533.121","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13175"},{"key":"2026012205050798000_67.1.2402533.122","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1038\/s41598-021-88734-2","article-title":"Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis","volume":"11","author":"Cano-Jim\u00e9nez","year":"2021","journal-title":"Sci Rep"},{"key":"2026012205050798000_67.1.2402533.123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000502551","article-title":"Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality","volume":"98","author":"Hyldgaard","year":"2019","journal-title":"Respiration"},{"key":"2026012205050798000_67.1.2402533.124","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2026012205050798000_67.1.2402533.125","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/resp.13848","article-title":"Risk prediction model in rheumatoid arthritis-associated interstitial lung disease","volume":"25","author":"Kim","year":"2020","journal-title":"Respirology"},{"key":"2026012205050798000_67.1.2402533.126","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2026012205050798000_67.1.2402533.127","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew391"},{"key":"2026012205050798000_67.1.2402533.128","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac208"},{"key":"2026012205050798000_67.1.2402533.129","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-06040-8"},{"key":"2026012205050798000_67.1.2402533.130","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"2026012205050798000_67.1.2402533.131","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead027"},{"key":"2026012205050798000_67.1.2402533.132","doi-asserted-by":"crossref","first-page":"152004","DOI":"10.1016\/j.semarthrit.2022.152004","article-title":"Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options","volume":"55","author":"Chen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026012205050798000_67.1.2402533.133","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.061"},{"key":"2026012205050798000_67.1.2402533.134","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/mr\/roac115","article-title":"Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: an ANSWER cohort study","volume":"33","author":"Makino","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026012205050798000_67.1.2402533.135","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2021.28.4.234"},{"key":"2026012205050798000_67.1.2402533.136","doi-asserted-by":"crossref","first-page":"151626","DOI":"10.1155\/2015\/151626","article-title":"Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis","volume":"2015","author":"Rocha-Mu\u00f1oz","year":"2015","journal-title":"J Immunol Res"},{"key":"2026012205050798000_67.1.2402533.137","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3707-5"},{"key":"2026012205050798000_67.1.2402533.138","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1879346"},{"key":"2026012205050798000_67.1.2402533.139","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.7.668"},{"key":"2026012205050798000_67.1.2402533.140","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"2026012205050798000_67.1.2402533.141","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003491"},{"key":"2026012205050798000_67.1.2402533.142","doi-asserted-by":"crossref","first-page":"SI286","DOI":"10.1093\/rheumatology\/kead277","article-title":"Rheumatoid arthritis, quantitative parenchymal lung features, and mortality among smokers","volume":"62","author":"McDermott","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.143","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229997"},{"key":"2026012205050798000_67.1.2402533.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.11.035"},{"key":"2026012205050798000_67.1.2402533.146","doi-asserted-by":"crossref","first-page":"152187","DOI":"10.1016\/j.semarthrit.2023.152187","article-title":"Survival of adults with rheumatoid arthritis associated interstitial lung disease \u2013 a systematic review and meta-analysis","volume":"60","author":"Farquhar","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2026012205050798000_67.1.2402533.147","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","article-title":"Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients","volume":"28","author":"Fujiki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026012205050798000_67.1.2402533.148","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq149"},{"key":"2026012205050798000_67.1.2402533.149","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.150","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.003"},{"key":"2026012205050798000_67.1.2402533.151","doi-asserted-by":"crossref","first-page":"1096203","DOI":"10.3389\/fmed.2022.1096203","article-title":"Clinical features and outcomes of patients with myositis associated-interstitial lung disease","volume":"9","author":"Karampitsakos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.152","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/14397595.2015.1134392","article-title":"Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"26","author":"Kotani","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2026012205050798000_67.1.2402533.153","doi-asserted-by":"crossref","first-page":"290797","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"2026012205050798000_67.1.2402533.154","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"2026012205050798000_67.1.2402533.155","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.01.014"},{"key":"2026012205050798000_67.1.2402533.156","doi-asserted-by":"crossref","first-page":"728487","DOI":"10.3389\/fmed.2021.728487","article-title":"The value of effective lung ventilation area ratio based on CT image analysis is a new index to predict the shorter outcome of anti-melanoma differentiation-associated protein 5 positive dermatomyositis associated interstitial lung disease: a single-center retrospective study","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.157","doi-asserted-by":"crossref","first-page":"17070","DOI":"10.1038\/s41598-021-96292-w","article-title":"A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis","volume":"11","author":"Xu","year":"2021","journal-title":"Sci Rep"},{"key":"2026012205050798000_67.1.2402533.158","doi-asserted-by":"crossref","first-page":"768052","DOI":"10.3389\/fmed.2021.768052","article-title":"A computed tomography radiomics-based prediction model on interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.159","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10067-021-06033-7","article-title":"Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study","volume":"41","author":"Yamaguchi","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.160","doi-asserted-by":"crossref","first-page":"e22978","DOI":"10.1002\/jcla.22978","article-title":"Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease","volume":"33","author":"Ye","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"2026012205050798000_67.1.2402533.161","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","article-title":"Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"55","author":"Yoshida","year":"2017","journal-title":"Respir Investig"},{"key":"2026012205050798000_67.1.2402533.162","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/mr\/roab017","article-title":"Clinical significance of HScore and MS score comparison in the prognostic evaluation of anti-MDA5-positive patients with dermatomyositis and interstitial lung disease","volume":"32","author":"Zhao","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026012205050798000_67.1.2402533.163","doi-asserted-by":"crossref","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","article-title":"Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.164","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","article-title":"HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients","volume":"34","author":"Zou","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.165","doi-asserted-by":"crossref","first-page":"845988","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"2026012205050798000_67.1.2402533.166","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.167","doi-asserted-by":"crossref","first-page":"15692","DOI":"10.1038\/s41598-020-72752-7","article-title":"The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease","volume":"10","author":"Wakura","year":"2020","journal-title":"Sci Rep"},{"key":"2026012205050798000_67.1.2402533.168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073774"},{"key":"2026012205050798000_67.1.2402533.169","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-003-2026-1"},{"key":"2026012205050798000_67.1.2402533.170","first-page":"349","article-title":"Relationship between abnormalities on high-resolution computerized tomography, pulmonary function, and bronchoalveolar lavage in progressive systemic sclerosis","volume":"33","author":"Cakmak","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012205050798000_67.1.2402533.171","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1497"},{"key":"2026012205050798000_67.1.2402533.172","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-6-96"},{"key":"2026012205050798000_67.1.2402533.173","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00228.x"},{"key":"2026012205050798000_67.1.2402533.174","doi-asserted-by":"publisher","DOI":"10.1002\/art.22696"},{"key":"2026012205050798000_67.1.2402533.175","first-page":"22","article-title":"Assessments of pulmonary involvement in patients with systemic sclerosis","volume":"14","author":"Gohari Moghadam","year":"2011","journal-title":"Arch Iran Med"},{"key":"2026012205050798000_67.1.2402533.176","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/keab586","article-title":"Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease","volume":"61","author":"He","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.177","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0154-4"},{"key":"2026012205050798000_67.1.2402533.178","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.21037\/jtd-20-2596","article-title":"Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease","volume":"13","author":"Kase","year":"2021","journal-title":"J Thorac Dis"},{"key":"2026012205050798000_67.1.2402533.179","doi-asserted-by":"publisher","DOI":"10.1002\/art.11042"},{"key":"2026012205050798000_67.1.2402533.180","first-page":"765","article-title":"Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis","volume":"27","author":"Meloni","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.181","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3390\/microorganisms9050932","article-title":"The role of lung colonization in connective tissue disease-associated interstitial lung disease","volume":"9","author":"Ricci","year":"2021","journal-title":"Microorganisms"},{"key":"2026012205050798000_67.1.2402533.182","first-page":"35","article-title":"The differing patterns of subclinical pulmonary involvement in connective tissue diseases as shown by application of factor analysis","volume":"19","author":"Salaffi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.183","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.3.263"},{"key":"2026012205050798000_67.1.2402533.184","doi-asserted-by":"publisher","DOI":"10.1186\/ar2766"},{"key":"2026012205050798000_67.1.2402533.185","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00296-010-1390-9","article-title":"Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters","volume":"31","author":"Volpinari","year":"2011","journal-title":"Rheumatol Int"},{"key":"2026012205050798000_67.1.2402533.186","doi-asserted-by":"publisher","DOI":"10.1002\/art.20265"},{"key":"2026012205050798000_67.1.2402533.187","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12318"},{"key":"2026012205050798000_67.1.2402533.188","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.5.1489"},{"key":"2026012205050798000_67.1.2402533.189","doi-asserted-by":"crossref","first-page":"e8513","DOI":"10.1590\/1414-431x20198513","article-title":"Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension","volume":"52","author":"Andrade","year":"2019","journal-title":"Braz J Med Biol Res"},{"key":"2026012205050798000_67.1.2402533.190","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel221"},{"key":"2026012205050798000_67.1.2402533.191","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054866"},{"key":"2026012205050798000_67.1.2402533.192","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026012205050798000_67.1.2402533.193","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080447"},{"key":"2026012205050798000_67.1.2402533.194","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1867-1"},{"key":"2026012205050798000_67.1.2402533.195","first-page":"S142","article-title":"Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease","volume":"33","author":"Rizzi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.196","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02452"},{"key":"2026012205050798000_67.1.2402533.197","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijcard.2016.03.084","article-title":"Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis","volume":"212","author":"Vandecasteele","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012205050798000_67.1.2402533.198","first-page":"122","article-title":"Six-minute walk test in or out in evaluation of systemic sclerosis patients?","volume":"35","author":"Vandecasteele","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.199","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2012.02133.x"},{"key":"2026012205050798000_67.1.2402533.200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chest.2022.01.007","article-title":"Acute respiratory deterioration in rheumatoid arthritis-associated interstitial lung disease: a single-center study","volume":"162","author":"Kwon","year":"2022","journal-title":"Chest"},{"key":"2026012205050798000_67.1.2402533.201","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151067"},{"key":"2026012205050798000_67.1.2402533.202","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00296-018-4050-0","article-title":"Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies","volume":"38","author":"Mugii","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026012205050798000_67.1.2402533.203","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201253"},{"key":"2026012205050798000_67.1.2402533.204","doi-asserted-by":"crossref","first-page":"778649","DOI":"10.3389\/fphar.2021.778649","article-title":"Autoimmune progressive fibrosing interstitial lung disease: predictors of fast decline","volume":"12","author":"Nagy","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026012205050798000_67.1.2402533.205","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000598"},{"key":"2026012205050798000_67.1.2402533.206","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012205050798000_67.1.2402533.207","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep284"},{"key":"2026012205050798000_67.1.2402533.208","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.209","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu456"},{"key":"2026012205050798000_67.1.2402533.210","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"2026012205050798000_67.1.2402533.211","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2026012205050798000_67.1.2402533.212","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(06)80166-6"},{"key":"2026012205050798000_67.1.2402533.213","first-page":"604","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Quality of Life Research"},{"key":"2026012205050798000_67.1.2402533.214","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.1.ats898"},{"key":"2026012205050798000_67.1.2402533.215","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201581"},{"key":"2026012205050798000_67.1.2402533.216","doi-asserted-by":"publisher","DOI":"10.1378\/chest.93.3.580"},{"key":"2026012205050798000_67.1.2402533.217","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2026012205050798000_67.1.2402533.218","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/resp.13293","article-title":"Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease","volume":"23","author":"Suzuki","year":"2018","journal-title":"Respirology"},{"key":"2026012205050798000_67.1.2402533.219","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001167"},{"key":"2026012205050798000_67.1.2402533.220","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1007\/s10067-021-05693-9","article-title":"Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability","volume":"40","author":"Topcu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.221","first-page":"A5353","article-title":"Living with idiopathic pulmonary fibrosis (L-IPF): developing a patient-reported symptom and impact questionnaire to assess health-related quality of life in IPF","volume":"195","author":"Graney","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012205050798000_67.1.2402533.222","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1600-0838.2009.00985.x","article-title":"An index for breathlessness and leg fatigue","volume":"20","author":"Borg","year":"2010","journal-title":"Scand J Med Sci Sports"},{"key":"2026012205050798000_67.1.2402533.223","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10067-020-05375-y","article-title":"Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests","volume":"40","author":"Carnevale","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.224","doi-asserted-by":"crossref","first-page":"1106560","DOI":"10.3389\/fmed.2023.1106560","article-title":"Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: a cohort study","volume":"10","author":"Chiu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.225","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-200109000-00015"},{"key":"2026012205050798000_67.1.2402533.226","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.033"},{"key":"2026012205050798000_67.1.2402533.227","doi-asserted-by":"crossref","first-page":"381","DOI":"10.21037\/qims.2016.08.08","article-title":"Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients","volume":"6","author":"Wangkaew","year":"2016","journal-title":"Quant Imaging Med Surg"},{"key":"2026012205050798000_67.1.2402533.228","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"2026012205050798000_67.1.2402533.229","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093"},{"key":"2026012205050798000_67.1.2402533.230","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201802-079OC"},{"key":"2026012205050798000_67.1.2402533.231","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0108"},{"key":"2026012205050798000_67.1.2402533.232","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.233","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2223-2"},{"key":"2026012205050798000_67.1.2402533.234","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208929"},{"key":"2026012205050798000_67.1.2402533.235","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02182-2018"},{"key":"2026012205050798000_67.1.2402533.236","doi-asserted-by":"crossref","first-page":"SI32","DOI":"10.1093\/rheumatology\/keac319","article-title":"Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation","volume":"62","author":"Pugnet","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.237","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4172\/2161-1149.1000154","article-title":"Development of a composite outcome measure for systemic sclerosis related interstitial lung disease","volume":"5","author":"Volkmann","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026012205050798000_67.1.2402533.238","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.41085","article-title":"Using transitional changes on high-resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis-related interstitial lung disease","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.239","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222564"},{"key":"2026012205050798000_67.1.2402533.240","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4046\/trd.2020.0043","article-title":"Short-term lung function changes and predictors of progressive systemic sclerosis-related interstitial lung disease","volume":"83","author":"Kaenmuang","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2026012205050798000_67.1.2402533.241","first-page":"S111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.242","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir Res"},{"key":"2026012205050798000_67.1.2402533.243","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026012205050798000_67.1.2402533.244","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases \u2013 subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.245","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac535"},{"key":"2026012205050798000_67.1.2402533.246","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026012205050798000_67.1.2402533.247","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"2026012205050798000_67.1.2402533.248","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4"},{"key":"2026012205050798000_67.1.2402533.249","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0872-2"},{"key":"2026012205050798000_67.1.2402533.250","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002859"},{"key":"2026012205050798000_67.1.2402533.251","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522"},{"key":"2026012205050798000_67.1.2402533.252","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.253","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-022-02095-6","article-title":"Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects","volume":"23","author":"Maher","year":"2022","journal-title":"Respir Res"},{"key":"2026012205050798000_67.1.2402533.254","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev016"},{"key":"2026012205050798000_67.1.2402533.255","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"2026012205050798000_67.1.2402533.256","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.257","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"2026012205050798000_67.1.2402533.258","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.259","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2026012205050798000_67.1.2402533.260","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.261","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"2026012205050798000_67.1.2402533.262","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00408-019-00276-7","article-title":"Clinical characteristics and natural history of autoimmune forms of interstitial lung disease: a single-center experience","volume":"197","author":"Chartrand","year":"2019","journal-title":"Lung"},{"key":"2026012205050798000_67.1.2402533.263","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/rheumatology\/keac651","article-title":"Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.264","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.265","first-page":"e2022029","article-title":"Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease","volume":"39","author":"Sahin Eroglu","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012205050798000_67.1.2402533.266","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.002"},{"key":"2026012205050798000_67.1.2402533.267","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.268","doi-asserted-by":"crossref","first-page":"871861","DOI":"10.3389\/fmed.2022.871861","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.269","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.270","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01641-2018"},{"key":"2026012205050798000_67.1.2402533.271","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133702"},{"key":"2026012205050798000_67.1.2402533.272","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045"},{"key":"2026012205050798000_67.1.2402533.273","doi-asserted-by":"publisher","DOI":"10.1002\/art.23571"},{"key":"2026012205050798000_67.1.2402533.274","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"2026012205050798000_67.1.2402533.275","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05530-5"},{"key":"2026012205050798000_67.1.2402533.276","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"2026012205050798000_67.1.2402533.277","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026012205050798000_67.1.2402533.278","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.279","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.280","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel112"},{"key":"2026012205050798000_67.1.2402533.281","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"key":"2026012205050798000_67.1.2402533.282","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1346-8138.15274","article-title":"Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"47","author":"Matsuda","year":"2020","journal-title":"J Dermatol"},{"key":"2026012205050798000_67.1.2402533.283","first-page":"136","article-title":"Treatment of primary Sj\u00f6gren's syndrome-related interstitial lung disease: a retrospective cohort study","volume":"37","author":"Amlani","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012205050798000_67.1.2402533.284","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026"},{"key":"2026012205050798000_67.1.2402533.285","doi-asserted-by":"crossref","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026012205050798000_67.1.2402533.286","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-021-01705-8","article-title":"Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients","volume":"16","author":"Yang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2026012205050798000_67.1.2402533.287","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026012205050798000_67.1.2402533.288","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012205050798000_67.1.2402533.289","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.052"},{"key":"2026012205050798000_67.1.2402533.290","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026012205050798000_67.1.2402533.291","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026012205050798000_67.1.2402533.292","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002477"},{"key":"2026012205050798000_67.1.2402533.293","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211682"},{"key":"2026012205050798000_67.1.2402533.294","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0714OC"},{"key":"2026012205050798000_67.1.2402533.295","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7"},{"key":"2026012205050798000_67.1.2402533.296","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213"},{"key":"2026012205050798000_67.1.2402533.297","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000384"},{"key":"2026012205050798000_67.1.2402533.298","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.299","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003"},{"key":"2026012205050798000_67.1.2402533.300","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02071-2022"},{"key":"2026012205050798000_67.1.2402533.301","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"key":"2026012205050798000_67.1.2402533.302","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.303","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180778"},{"key":"2026012205050798000_67.1.2402533.304","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu166"},{"key":"2026012205050798000_67.1.2402533.305","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190505"},{"key":"2026012205050798000_67.1.2402533.306","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-hour post-dose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"key":"2026012205050798000_67.1.2402533.307","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"key":"2026012205050798000_67.1.2402533.308","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"2026012205050798000_67.1.2402533.309","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.02.015"},{"key":"2026012205050798000_67.1.2402533.310","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912"},{"key":"2026012205050798000_67.1.2402533.311","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00163911"},{"key":"2026012205050798000_67.1.2402533.312","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"2026012205050798000_67.1.2402533.313","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"2026012205050798000_67.1.2402533.314","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4382-x"},{"key":"2026012205050798000_67.1.2402533.315","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa577"},{"key":"2026012205050798000_67.1.2402533.316","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000473"},{"key":"2026012205050798000_67.1.2402533.317","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/jcm9041082","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"2026012205050798000_67.1.2402533.318","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"2026012205050798000_67.1.2402533.319","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005615"},{"key":"2026012205050798000_67.1.2402533.320","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab317"},{"key":"2026012205050798000_67.1.2402533.321","first-page":"CD001157","article-title":"Cyclophosphamide for rheumatoid arthritis","volume":"2000","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012205050798000_67.1.2402533.322","first-page":"CD001461","article-title":"Azathioprine for treating rheumatoid arthritis","volume":"2000","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012205050798000_67.1.2402533.323","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00337-2020"},{"key":"2026012205050798000_67.1.2402533.324","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102830"},{"key":"2026012205050798000_67.1.2402533.325","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s10067-016-3357-z","article-title":"Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Zamora-Legoff","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2026012205050798000_67.1.2402533.326","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043"},{"key":"2026012205050798000_67.1.2402533.327","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2026012205050798000_67.1.2402533.328","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"2026012205050798000_67.1.2402533.329","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/acr2.11210","article-title":"Rituximab versus mycophenolate in the treatment of recalcitrant connective tissue disease-associated interstitial lung disease","volume":"3","author":"Zhu","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2026012205050798000_67.1.2402533.330","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","article-title":"Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial","volume":"61","author":"Volkmann","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026012205050798000_67.1.2402533.331","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100\u2009weeks: data from a randomized controlled trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026012205050798000_67.1.2402533.332","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00215-6"},{"key":"2026012205050798000_67.1.2402533.333","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2443"},{"key":"2026012205050798000_67.1.2402533.334","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012205050798000_67.1.2402533.336","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214816"},{"key":"2026012205050798000_67.1.2402533.337","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026012205050798000_67.1.2402533.338","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909"},{"key":"2026012205050798000_67.1.2402533.339","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/a-2017-8971","article-title":"Leitlinie Interdisziplin\u00e4re Diagnostik interstitieller Lungenerkrankungen im Erwachsenenalter [Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]","volume":"77","author":"Kreuter","year":"2023","journal-title":"Pneumologie"},{"key":"2026012205050798000_67.1.2402533.340","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026012205050798000_67.1.2402533.341","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003350"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02533-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:05:54Z","timestamp":1769087154000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02533-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":341,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/13993003.02533-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02533-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}